David Shapiro, M.D.

Dr. David Shapiro has over 30 years of clinical development experience in the pharmaceutical industry.  He has served as the Chief Medical Officer of Intercept Pharmaceuticals, Inc. since November 2017, having previously served as its Chief Medical Officer and Executive Vice President, Research & Development since 2008.  Dr. Shapiro founded a consulting company, Integrated Quality Resources, that focused on development stage biopharmaceutical companies and was active in this role from 2005 to 2008.  From 2000 to 2005, Dr. Shapiro was Executive Vice President, Medical Affairs and Chief Medical Officer of Idun Pharmaceuticals, Inc., prior to its acquisition by Pfizer Inc.  From 1995 to 1998, he was President of the Scripps Medical Research Center at Scripps Clinic.  He served as Vice President, Clinical Research at Gensia and as Director and Group Leader, Hypertension Clinical Research at Merck Research Laboratories from 1985 to 1990. 

Richard Maroun

Richard Maroun is an executive partner at Frazier Healthcare Partners, a private equity and venture capital firm specializing in healthcare-focused investments.  Before joining Frazier in 2015, Maroun was senior vice president and general counsel of Aptalis Pharmaceuticals from 2012 to 2014.  He has also held numerous senior executive roles for APP Pharmaceuticals, Abraxis BioScience and American BioScience Inc.  Mr. Maroun has worked with major financial organizations and independent law firms, and has held both legal and financial positions with companies including Merrill Lynch, Deloitte & Touche and McDonough, Holland & Allen.  Mr. Maroun currently serves on the board of Leiter’s Enterprises, a private portfolio company of Frazier Healthcare Partners, and the Board of Trustees of John Carroll University.  Mr. Maroun holds a J.D. from Santa Clara University Law School and a B.S. from John Carroll University.

Mark Kessel

Mr. Kessel is a partner of Symphony Capital, LLC, a private equity firm he co-founded in 2002 that invests in biopharmaceutical company clinical development programs.  He is also Of Counsel at Shearman & Sterling and a member of the firm’s capital markets group.  Previously, from 1971 to 2001, Mr. Kessel held various roles at Shearman & Sterling, including as managing partner leading the international law firm’s day-to-day operations.  He helped build the firm, serving as a leader in the healthcare, biopharmaceutical, agricultural biotech, high-tech, and financial services practices.  He also established the firm’s San Francisco office, serving as its managing partner and turning it into the leader in M&A, capital markets, corporate governance, and intellectual property and licensing issues.  Mr. Kessel has previously served on several public biopharmaceutical company boards.  Mr. Kessel holds a J.D. magna cum laude from Syracuse University College of Law and a B.A. in Economics from The City College of New York. 

Taylor J. Crouch

Mr. Crouch has been our CEO and President since 2017 and has over 25 years of experience building and leading technology, expertise and product-based companies in the life sciences and biotech industries. Prior to Organovo, he managed and served as an operational investor in a group of leading clinical research site companies.  Specifically, Mr. Crouch served as Chief Executive Officer at eStudySite, a position he held from January 2009 to June 2016; as Executive Chairman of Meridien Research from December 2013 to September 2016; and as a Director of the National Research Institute from September 2011 through July 2016.  He was instrumental in building these three sister companies, and helping them to achieve significant and profitable growth and to become recognized leaders in their respective fields of infectious disease, CNS disorders and metabolic disease.  Prior to this, Mr. Crouch served as Senior Vice President of Operations/President International at Ligand Pharmaceuticals (NASDAQ: LGND) from 2005 to 2007, with responsibilities for new business development, technical operations, international sales and clinical research.  Prior to Ligand, he was President and Chief Operating Officer of Discovery Partners International (NASDAQ: formerly DPII – a large drug discovery services and technology provider).  Earlier in his career, he was Chief Executive Officer of Variagenics (NASDAQ: formerly VGNX – a leading pharmacogenomics company), Senior Vice President of Marketing and Sales at Parexel (NASDAQ: formerly PRXL) – a global CRO, and he also held international management positions in new product development and commercialization at Pfizer and Schering Plough.  Mr. Crouch serves on the Board of Directors of BIOCOM, an organization comprising 1,100 life sciences companies throughout California.  Mr. Crouch holds a BSE in chemical engineering, cum laude, from Princeton University and an MBA in international marketing and finance from the University of Chicago.

Carolyn Beaver, C.P.A.

Ms. Carolyn Beaver has over 30 years of audit and financial management experience.  She previously held several positions at Sequenom Inc., a life sciences testing company, including Chief Financial Officer and Senior Vice President from March 2015 to October 2016, Chief Financial Officer from June 2014 to March 2015 and Vice President and Chief Accounting Officer from June 2012 to March 2015.  Ms. Beaver was previously Corporate Vice President and Controller of Beckman Coulter, Inc., a biomedical laboratory instrument and test company, from August 2005 until June 2012, and was named Chief Accounting Officer in October 2005, a position she held until July 2011, following the acquisition of Beckman Coulter, Inc. by Danaher Corporation.  She also served as interim Chief Financial Officer of Beckman Coulter from July 2006 through October 2006.  Ms. Beaver was a director of Commerce National Bank, chair of its audit committee and a member of its asset/liability committee from 2005 until the bank was acquired in 2013.  Ms. Beaver served as an audit partner with KPMG LLP from 1987 to 2002.  She was named a director and member of the audit committee of MaxLinear, Inc., a high-performance broadband and networking semiconductor company, in December 2018.  Ms. Beaver received a Bachelor of Science degree in Business Administration from California State Polytechnic University, Pomona.

Kirk Malloy, Ph.D.

Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostic companies for over 20 years.  He is currently an independent consultant for life science companies and also serves as the Executive Chairman of Verogen, Inc.  Previously, he was the Senior Vice President and General Manager of the Life Sciences and Applied Markets Business of Illumina, Inc., a position he held from January 2014 to April 2016. Dr. Malloy joined Illumina in 2002, and served in a number of executive leadership positions, including Vice President, Global Customer Solutions from 2007 to 2013, Vice President, Global Quality from 2005 to 2007 and Senior Director, Global Customer Solutions from 2002 to 2005. Prior to joining Illumina, Dr. Malloy held commercial leadership positions at Biosite, Inc. and commercial management positions at Qiagen, Inc. Before joining the industry, Dr. Malloy spent several years as an academic scientist teaching and conducting research. Dr. Malloy received his B.S. degrees in Biology and Marine Science from the University of Miami and his M.S. and Ph.D. degrees in Marine Biology/Biochemistry from the University of Delaware and held post-doctoral positions at Boston University and Northeastern University. Dr. Malloy has 12 peer-reviewed publications and book chapters, dozens of invited and contributed scientific presentations and has been a reviewer for various scientific journals.